BiotechTube
Aleva Neurotherapeutics

Aleva Neurotherapeutics

Lausanne, Switzerland· Est.
aleva-neuro.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $30M

Overview

Aleva Neurotherapeutics is a Swiss innovator and commercial-stage company in the neuromodulation space, specializing in high-precision Directional Deep Brain Stimulation (DBS). The company's core technology combines a directional lead with 24 contacts and a Multiple Independent Current Control (MICC) generator, designed to provide superior targeting of brain structures to widen the therapeutic window and reduce side effects. Having achieved CE mark for its directSTIM™ system, Aleva is now focused on commercial rollout in Europe via partnerships with leading neurological clinics, backed by a strong IP portfolio of over 90 granted patents. The company leverages Swiss precision manufacturing and is actively expanding its team to support growth and further technological development.

Parkinson's DiseaseEssential TremorNeurological Disorders

Technology Platform

Directional Deep Brain Stimulation (DBS) system featuring a directional lead with 24 contacts and a Multiple Independent Current Control (MICC) generator for precise, steerable electrical stimulation of neural tissue.

Funding History

2
Total raised:$30M
Series B$20M
Series A$10M

Opportunities

The primary opportunity is to capture market share in the large, established DBS market by addressing a key limitation of current technology: non-specific, omnidirectional stimulation that causes side effects and leaves many patients as non-responders.
By demonstrating superior outcomes, Aleva can also potentially expand the treatable patient population and establish a new standard of care in precision neuromodulation.

Risk Factors

Key risks include intense competition from large, well-funded incumbents; the challenge of driving adoption in a conservative medical market; the need to generate robust long-term clinical data; and the financial and regulatory hurdles of expanding into major markets like the United States.

Competitive Landscape

Aleva competes in the deep brain stimulation device market, which is dominated by large medical technology corporations like Medtronic, Boston Scientific, and Abbott. Its competitive advantage is based on its pioneering directional stimulation technology, which aims to provide superior precision and clinical outcomes compared to the traditional omnidirectional systems offered by these incumbents.

More companies in Neuroscience & CNS →More companies in Switzerland →